Calistoga Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines targeting the PI3kinase and related pathways for the treatment of cancer and inflammatory diseases to
improve the health of our patients.

  
FEATURES
NEWS
 

 

March 10, 2008
Calistoga Pharmaceuticals initiates its First Clinical Study of Novel Oral PI3K Delta Compound, CAL-101...read more>

February 14th, 2008
Reuters – New target promises better asthma and allergy drugs...read more>

February 13th, 2008
Calistoga Pharmaceuticals Appoints R. Lee Douglas to
BOD ...read more>

January 3rd, 2008
Calistoga Pharmaceuticals announces completion of its Series A Financing - Investors increased funding by 25% to total $26.2 Million...read more>